Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Capri Holdings Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.46 (market cap $5.07B), while Capri Holdings Ltd trades at $15.2 (market cap $1.75B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.9× Capri Holdings Ltd's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | CPRI | |
|---|---|---|
Market Cap | $5.07B | $1.75B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $27.66 |
52-Week Low | $20.06 | $14.98 |
Enterprise Value | $4.19B | $3.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
CPRI trades at $15.43, down 65% over five years but showing recent earnings momentum with three consecutive quarterly beats. The stock faces bearish technical signals with moving averages indicating downward pressure, while fundamentals reveal declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Analyst consensus sits at $19.60 with mixed ratings (44% Buy, 52% Hold), reflecting cautious optimism about the company's turnaround strategy post-Versace sale.
The investment case hinges on CPRI's ability to stabilize Michael Kors and grow Jimmy Choo profitability, but risks include ongoing revenue declines, luxury market softness, and high debt levels. With the current price near 52-week lows and 27% upside to consensus target, the stock offers potential for recovery if management executes its revamp plans successfully, though macroeconomic headwinds and brand challenges remain significant concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
